A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
about
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
description
clinical trial
@en
klinisch onderzoek
@nl
name
A Study of Vismodegib (GDC-044 ...... r Metastatic Colorectal Cancer
@en
type
label
A Study of Vismodegib (GDC-044 ...... r Metastatic Colorectal Cancer
@en
prefLabel
A Study of Vismodegib (GDC-044 ...... r Metastatic Colorectal Cancer
@en
P4844
P1476
A Randomized, Placebo-Controll ...... r Metastatic Colorectal Cancer
@en
P3098
NCT00636610
P580
2008-05-01T00:00:00Z
P582
2010-12-01T00:00:00Z